TESARO, Inc. (TSRO) Scheduled to Post Quarterly Earnings on Wednesday
TESARO, Inc. (NASDAQ:TSRO) is set to announce its earnings results after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($1.16) per share for the quarter.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter in the previous year, the company posted ($1.28) earnings per share. TESARO’s revenue for the quarter was down 17.6% compared to the same quarter last year. On average, analysts expect TESARO to post $-8.9 EPS for the current fiscal year and $-5.11 EPS for the next fiscal year.
TESARO, Inc. (NASDAQ TSRO) opened at 112.39 on Wednesday. The stock’s market capitalization is $6.09 billion. The stock has a 50 day moving average price of $120.07 and a 200-day moving average price of $132.14. TESARO, Inc. has a 12-month low of $106.64 and a 12-month high of $192.94.
Several analysts recently weighed in on the company. Gabelli assumed coverage on TESARO in a research note on Friday, July 7th. They issued a “buy” rating and a $175.00 price objective on the stock. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Credit Suisse Group set a $198.00 target price on TESARO and gave the stock a “buy” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $199.00 target price on shares of TESARO in a report on Sunday, September 10th. Finally, BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. TESARO currently has an average rating of “Hold” and an average price target of $166.10.
In related news, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,692 shares of company stock valued at $4,628,976. 34.60% of the stock is owned by corporate insiders.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.